| 1 |
35263700 | Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. | 2022 May |
2 |
| 2 |
34244306 | Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. | 2021 Jul |
5 |
| 3 |
34572047 | Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells. | 2021 Sep 12 |
3 |
| 4 |
34957309 | In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer. | 2021 |
2 |
| 5 |
29557271 | Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. | 2019 Mar |
1 |
| 6 |
31670920 | EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. | 2019 |
1 |
| 7 |
29237052 | Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. | 2018 Mar 16 |
1 |
| 8 |
29632071 | The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation. | 2018 Jun 1 |
1 |
| 9 |
30208932 | Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. | 2018 Sep 12 |
1 |
| 10 |
30614492 | Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay. | 2018 Dec 19 |
1 |
| 11 |
33418733 | Controlled Three-Dimensional Tumor Microenvironments Recapitulate Phenotypic Features and Differential Drug Response in Early vs Advanced Stage Breast Cancer. | 2018 Feb 12 |
1 |
| 12 |
27159275 | A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells. | 2016 |
3 |
| 13 |
25279503 | Bioenergetic differences between MCF-7 and T47D breast cancer cells and their regulation by oestradiol and tamoxifen. | 2015 Jan 1 |
1 |
| 14 |
25014417 | Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant. | 2014 Sep 5 |
1 |
| 15 |
25064027 | Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells. | 2014 Jul 26 |
2 |
| 16 |
23704208 | c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. | 2013 Jul 15 |
1 |
| 17 |
23892277 | Estradiol and tamoxifen regulate NRF-1 and mitochondrial function in mouse mammary gland and uterus. | 2013 Oct |
2 |
| 18 |
19858209 | G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation. | 2009 Dec 25 |
2 |
| 19 |
18499701 | Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. | 2008 Jul |
1 |
| 20 |
18001325 | Agonist activity of the 3-hydroxy metabolites of tibolone through the oestrogen receptor in the mouse N20.1 oligodendrocyte cell line and normal human astrocytes. | 2007 Dec |
1 |
| 21 |
14715875 | Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. | 2004 Jan |
2 |
| 22 |
15297425 | Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. | 2004 Aug 1 |
1 |
| 23 |
15457130 | Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. | 2004 Oct |
2 |
| 24 |
12648521 | 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. | 2003 Jan |
2 |
| 25 |
12495475 | Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro. | 2002 Dec |
2 |
| 26 |
11306182 | Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha. | 2001 Mar 28 |
1 |
| 27 |
11325832 | Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. | 2001 May 1 |
1 |
| 28 |
11530283 | Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. | 2001 Jul |
3 |
| 29 |
11719281 | Estrogen response element binding induces alterations in estrogen receptor-alpha conformation as revealed by susceptibility to partial proteolysis. | 2001 Dec |
4 |
| 30 |
10418989 | Suppression of gene expression by tethering KRAB domain to promoter of ER target genes. | 1999 Apr-Jun |
1 |
| 31 |
9566718 | Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. | 1998 Mar 13 |
2 |
| 32 |
9806352 | Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements. | 1998 Aug 25 |
3 |
| 33 |
8738832 | Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro. | 1996 May |
1 |
| 34 |
8809185 | Footprint analysis of estrogen receptor binding to adjacent estrogen response elements. | 1996 Apr |
5 |
| 35 |
7873531 | Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. | 1995 Feb 28 |
6 |
| 36 |
1491696 | Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. | 1992 Dec |
3 |